Clinical Trials | July 27, 2022
Nuance Pharma announces the completion of dosing for all NTM-001 Phase 1 clinical study
The NTM-001 Phase I clinical study is expected to be completed by the end of 2022
The NTM-001 Phase I clinical study is expected to be completed by the end of 2022
This will not only strengthen the country’s overall position in the global vaccine industry but also reduce its reliance on foreign vaccines
AstraZeneca and Indian Society of Nephrology aim to help clinicians and healthcare practitioners to provide holistic kidney care to their patients.
The product will be manufactured at Lupin's facility in Nagpur, India.
The Award reinforces Cadila’s digital initiatives which is backed by innovation, research & development and robust frameworks.
The region's digital health market, valued at USD 40.3 billion in 2021, is expected to expand to USD 326.7 billion by 2030 at a CAGR of 26.5 per cent.
Sun Pharma will receive from Cassiopea the exclusive right to develop and commercialize WINLEVI in Japan, Australia, New Zealand, Brazil, Mexico and Russia.
An outlay of Rs. 1,500 crore has been approved for strengthening/ up-gradation of these NIPERs for the period 2021-22 to 2025-26.
Dr. Mona frequently treats children experiencing localized reactions from insect bites and stings.
Subscribe To Our Newsletter & Stay Updated
